-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-01-29
GRI:NSD-GRI Bio Inc. (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.63Change
0.00 (0.00)%Market Cap
N/AVolume
0.12MAnalyst Target
N/AN/A
Verdict
Values as of: 2025-01-29
COMMON STOCK | Biotechnology |
Last Closing
USD 0.63Change
0.00 (0.00)%Market Cap
N/AVolume
0.12MAnalyst Target
N/AN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
+0.84 (+0.19%) |
USD 104.84B |
REGN | Regeneron Pharmaceuticals Inc |
+0.94 (+0.14%) |
USD 78.92B |
ARGX | argenx NV ADR |
+6.65 (+1.03%) |
USD 39.62B |
ALNY | Alnylam Pharmaceuticals Inc |
-5.20 (-1.86%) |
USD 30.22B |
MRNA | Moderna Inc |
-4.22 (-9.39%) |
USD 18.29B |
RPRX | Royalty Pharma Plc |
+0.01 (+0.03%) |
USD 18.12B |
SMMT | Summit Therapeutics PLC |
-1.86 (-7.91%) |
USD 17.52B |
UTHR | United Therapeutics Corporatio.. |
+1.90 (+0.51%) |
USD 15.91B |
INCY | Incyte Corporation |
+0.57 (+0.78%) |
USD 13.41B |
BMRN | Biomarin Pharmaceutical Inc |
+0.21 (+0.33%) |
USD 12.74B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
IUKP:SW | iShares UK Property UCITS.. | 3.33 % | 0.00 % |
N/A |
USD 0.59B |
UKPH:XETRA | iShares UK Property UCITS.. | 3.23 % | 0.00 % |
-0.02 (-0.48%) |
N/A |
IUKP:LSE | iShares UK Property UCITS | 0.00 % | 0.00 % |
-2.50 (-0.48%) |
USD 0.59B |
UKRE:LSE | iShares MSCI Target UK Re.. | 0.00 % | 0.00 % |
-2.10 (-0.48%) |
USD 0.12B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -23.95% | 13% | F | 8% | B- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -23.95% | 13% | F | 8% | B- | ||
Trailing 12 Months | |||||||
Capital Gain | -97.01% | 3% | F | 1% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -97.01% | 3% | F | 1% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -100.00% | N/A | F | N/A | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -100.00% | N/A | F | N/A | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -36.86% | 8% | B- | 4% | F | ||
Dividend Return | -36.86% | 8% | B- | 4% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 47.08% | 66% | D+ | 41% | F | ||
Risk Adjusted Return | -78.30% | 12% | F | 7% | C- | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector